InMed Pharmaceuticals Reports Positive Preclinical Results for Alzheimer's Drug INM-901

Key Facts

1InMed Pharmaceuticals announced positive preclinical data for its INM-901 Alzheimer's drug candidate.

2The study demonstrated the drug's ability to reduce neuroinflammation in 3D human brain organoid models.

3The research was conducted in collaboration with Stem Pharm to de-risk the program ahead of human clinical trials.

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced promising preclinical data for its drug candidate INM-901, aimed at treating Alzheimer's disease. The study, conducted in collaboration with Stem Pharm, demonstrated the drug's effectiveness in reducing neuroinflammation within 3D human brain organoid models. This milestone validates the transition of successful animal model results into human-relevant tissue systems, strengthening the therapeutic rationale. By utilizing advanced organoid technology, the company aims to de-risk the development program before advancing to Phase 1 clinical trials. Investors are closely monitoring these developments as they represent a significant step forward in the company's biotech pipeline. The positive results highlight INM-901's potential as a multi-targeted approach to addressing the complexities of neurodegenerative diseases.

Open on chart